Skip to main content
NIH funding notice RFA-DA-25-011

Exploratory studies to investigate mechanisms of HIV infection, replication, latency, and/or pathogenesis in the context of substance use disorders (R01 Clinical Trial Not Allowed)

Closed on September 10, 2024.

Posted
October 5, 2023
Close date
September 10, 2024
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

1 competing award (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $804,728 in first-year total cost, median $804,728.

Most frequent study sections

  1. Special Emphasis Panel[ZDA1 SXC-N (J1)]1

Most frequent institutions

  1. UNIVERSITY OF CALIFORNIA RIVERSIDE1
Competing awards under RFA-DA-25-011 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2025Methamphetamine and Cysteinyl Leukotrienes in HIV Persistence1R01DA063181-01KAUL, MARCUSUNIVERSITY OF CALIFORNIA RIVERSIDE, CA$804,728ZDA1

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-10-0.1.1. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.

RFA-DA-25-011: Exploratory studies to investigate mechanisms of HIV infection, replication, latency, and/or pathogenesis in the context of substance use disorders (R01 Clinical Trial Not Allowed) | ScienceDex | ConductScience